BRIEF-Basilea Pharmaceutica reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor

<span id="midArticle_start"/>May 5 (Reuters) - Basilea Pharmaceutica AG :

<span id="midArticle_0"/>* Said on Monday it reported start of first-in-human phase 1oncology study with oral panRAF kinase inhibitor

<span id="midArticle_1"/>* Said open-label dose-escalation phase 1 study is designedto investigate the safety and tolerability of once-daily oraldoses of BAL3833/CCT3833 in adult patients with advanced solidtumors

<span id="midArticle_2"/>
<span id="midArticle_3"/>Source text for Eikon:

<span id="midArticle_4"/>Further company coverage:

<span id="midArticle_5"/>(Gdynia Newsroom)

<span id="midArticle_6"/>

via Smart Health Shop Forum http://ift.tt/1Pktm2M